Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schwarz Omeprazole Strategy, Part 2: DTC Ads, No Further Price Cuts

Executive Summary

Schwarz is giving generic omeprazole a marketing push into the broader proton pump inhibitor category rather than reducing price to further capture Prilosec's share in the omeprazole segment

You may also be interested in...



Lek Launches Omeprazole; Third Generic Of Prilosec Enters Market

Novartis' Lek generic division is following Mylan with an "at risk" launch of generic omeprazole

Lek Launches Omeprazole; Third Generic Of Prilosec Enters Market

Novartis' Lek generic division is following Mylan with an "at risk" launch of generic omeprazole

Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold

Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category

Related Content

UsernamePublicRestriction

Register

PS042256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel